Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Evidence: MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

Active as of 2024-11-01

Generated Narrative: Evidence 236978

version: 61; Last updated: 2024-10-03 13:11:20+0000

Profile: ComparativeEvidence

url: Evidence MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

identifier: FEvIR Object Identifier/236978, outcomeId/313964, picoId/85798, sectionId/73215, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.22.57

version: 2.0.0-ballot

name: Genital_infectionfrom_MAGICapp_313964

title: MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

status: Active

date: 2024-11-01 10:20:00+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

author: Computable Publishing®: MAGIC-to-FEvIR Converter:

UseContexts

-CodeValue[x]
*Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence CommunicationComparativeEvidence

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

RelatedArtifacts

-TypeResourceReference
*Part OfMAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

assertion:

SGLT2 inhibitors increase the risk of genital infection compared with GLP-1 receptor agonists.

variableDefinition

org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code: population

description:

Adults with type 2 diabetes

note: population

observed: Adults with type 2 diabetes and CVD and CKD

variableDefinition

org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code: exposure

org/fhir/uv/ebm/StructureDefinition/variable-definition-comparator-category: GLP-1 RA

description:

GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA

note: exposure

observed: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA

variableDefinition

org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code: outcome

description:

Genital infection

note: outcome

observed: Genital infection

synthesisType: SYSTEMATIC_REVIEW

studyDesign: randomized assignment

statistic

description:

Risk Difference 15.8% (CI95 6.4% to 29.9%)

statisticType: Risk Difference

quantity: 0.158

SampleSizes

-NumberOfStudiesNumberOfParticipants
*21282

AttributeEstimates

-TypeRange
*CI950.064-0.299

statistic

description:

OR 5.0 (CI95 2.45 to 10.2)

statisticType: Odds Ratio

quantity: 5

SampleSizes

-NumberOfStudiesNumberOfParticipants
*21282

AttributeEstimates

-TypeRange
*CI952.45-10.2

certainty

type: Overall certainty

rating: High certainty

Subcomponents

-TypeRating
*Risk of BiasNOTSET
*InconsistencyNOTSET
*IndirectnessNOTSET
*ImprecisionNOTSET
*Publication BiasNOTSET